CoChat
Cited by 162

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Body Weight Changes Associated With Psychopharmacology

Vanina, Yelena, Podolskaya, Anna, Sedky, Karim, Shahab, Hasan, Siddiqui, Abufarah, Munshi, Firoz, Lippmann, Steven · 2002 · Psychiatric Services

Abstract

OBJECTIVE: The authors discuss changes in body weight associated with various psychopharmaceuticals. METHODS: A large number of articles and books about drug-induced changes in body weight, selected on the basis of various literature searches and the authors' clinical experiences with psychopharmaceuticals, were reviewed. RESULTS: Many psychotropic drugs with antipsychotic, mood stabilizing, and antidepressant properties are associated with weight gain. Others, such as fluoxetine, isocarboxazid, nefazadone, topiramate, and psychostimulants, may cause weight loss. The antipsychotic drugs chlorpromazine, clozapine, and olanzapine are often associated with weight gain. Among antidepressants, amitriptyline and mirtazapine are known to cause weight gain. However, reductions are sometimes observed, and each antidepressant has its own unique weight-effect profile. Mood stabilizers, especially valproate-related products, are also associated with weight gain. CONCLUSIONS: Careful monitoring and consideration of alternative therapies are essential.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ps.53.7.842

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 56

  1. Payne P, Dugdale A: Mechanisms for the control of body weight. Lancet 12:583-585, 1977 · DOI
  2. Aquila R, Emanuel M: Weight gain and antipsychotic medication. Journal of Clinical Psychiatry 60:336-337, 1999 · DOI
  3. Berken G, Weinstein D, Stern W: Weight gain: a side effect of tricyclic antidepressants. Journal of Affective Disorders 7:133-138, 1984 · DOI · Paper page
  4. Umbricht D, Kane J: Medical complications of new antipsychotic drugs. Schizophrenia Bulletin 22:475-483, 1996 · DOI
  5. Brady K: Weight gain associated with psychotropic drugs. Southern Medical Journal 82:611-617, 1989 · DOI
  6. Holden J, Holden U: Weight changes with schizophrenic psychosis and psychotropic drug therapy. Psychosomatics 9:551-561, 1970 · DOI
  7. Fallon I, Watt D, Sheperd M: Pimozide and fluphenazine decanoate in continuation therapy. Psychological Medicine 8:59-70, 1979 · DOI · Paper page
  8. Heikinen H, Outakoski J, Merilainen V, et al: Molindone and weight loss. Journal of Clinical Psychiatry 54:160-161, 1993
  9. Gardos G, Cole J: Weight reduction in schizophrenics by molindone. American Journal of Psychiatry 134:302-304, 1977 · DOI
  10. Lamberti S, Terrance B, Schwarzkopf S: Weight gain among schizophrenic patients treated with clozapine. American Journal of Psychiatry 149:689-690, 1992 · doi:10.1176/ajp.149.5.689
  11. Umbricht D, Pollack S, Kane J: Clozapine and weight gain. Journal of Clinical Psychiatry 55:157-160, 1994
  12. Bai Y, Lin C, Chen J, et al: Weight gain among patients on clozapine. Psychiatric Services 50:704-705, 1999 · DOI
  13. Meltzer H: Adverse effects of the atypical antipsychotics. Journal of Clinical Psychiatry 59:17-22, 1998
  14. Melkersson U, Hulting A, Bismar K: Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. Journal of Clinical Psychiatry 60:783-791, 1999 · DOI
  15. Wetterling T, Mubigbrodt H: Weight gain: side effect of atypical neuroleptics. Journal of Clinical Psychopharmacology 19:316-321, 1999 · DOI
  16. Gupta S, Droney T, Al-Samarrai S, et al: Olanzapine: weight gain and therapeutic efficacy. Journal of Clinical Psychopharmacology 19:273-274, 1999 · doi:10.1097/00004714-199906000-00014
  17. Beasley C: The safety of olanzapine. Journal of Clinical Psychiatry 15:19-21, 1997
  18. Tran P, Hamilton S, Kuntz A, et al: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 17:407-418, 1997 · DOI · Paper page
  19. Song F: Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. Journal of Clinical Psychopharmacology 11:65-71, 1997 · DOI
  20. Ganguli R, Brar J, Ayrton Z: Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophrenia Research 49:261-267, 2001 · DOI
  21. Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multicentered, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry 166:712-733, 1995 · DOI · Paper page
  22. Crockford D, Fisher G, Barker P: Risperidone, weight gain, and bulimia nervosa. Canadian Journal of Psychiatry 4:326-327, 1997 · DOI
  23. Wirshing D, Wirshing W, Kysar L, et al: Novel antipsychotics: weight gain liabilities. Journal of Clinical Psychiatry 60:358-363, 1999 · DOI · Paper page
  24. Borison R, Arvanitis L, Miller B, et al: ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. Journal of Clinical Psychopharmacology 16:158-169, 1996 · DOI · Paper page
  25. Barnes T, McPhillips M: Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. British Journal of Psychiatry 174(38S):34-43, 1999 · DOI
  26. Rosenfeld W, Shaefer P, Pace K: Weight loss patterns with topiramate therapy. Epilepsia 38:60-63, 1997 · doi:10.1111/j.1528-1157.1997.tb04516.x
  27. Gordon A, Price L: Mood stabilization and weight loss with topiramate. American Journal of Psychiatry 156:968-969, 1999 · DOI
  28. Vendsborg P, Bech P, Rafaelsen O: Lithium treatment and weight gain. Acta Psychiatrica Scandinavica 53:139-147, 1976 · DOI
  29. Peslow E, Dunner D, Fieve R, et al: Lithium carbonate and weight gain. Journal of Affective Disorders 2:303-310, 1980 · DOI
  30. Vendsborg P, Rafaelsen O: Lithium in man: effect on glucose tolerance and serum electrolytes. Acta Psychiatrica Scandinavica 43:601-610, 1973 · doi:10.1111/j.1600-0447.1973.tb04451.x
  31. Shopsin B, Stern S, Gershon S: Altered carbohydrate metabolism during treatment with lithium carbonate. Archives of General Psychiatry 28:566-571, 1972 · DOI
  32. Vendsborg P, Prytz S: Glucose tolerance and serum lipids in man after long-term lithium administration. Acta Psychiatrica Scandinavica 53:64-69, 1976 · doi:10.1111/j.1600-0447.1976.tb00059.x
  33. Sussman N, Ginsberg D: Effect of psychotropic drugs on weight. Psychiatric Annals 29:580-594, 1999 · doi:10.3928/0048-5713-19991001-08
  34. Davis R, Peters D, McTavish D: Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47:332-342, 1994 · doi:10.2165/00003495-199447020-00008
  35. Dinesen H, Lennart G, Andersen T, et al: Weight gain during treatment with valproate. Acta Neurologica Scandinavica 70:65-69, 1984 · doi:10.1111/j.1600-0404.1984.tb00804.x
  36. Verrotti A, Basciani F, Morresi S, et al: Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 53:230-232, 1999 · doi:10.1212/wnl.53.1.230
  37. Joffe R, Post R, Uhde T: Effect of carbamazepine on body weight in affectively ill patients. Journal of Clinical Psychiatry 47:313-314, 1986
  38. Lampl Y, Eshel Y, Rapaport A, et al: Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clinical Neuropharmacology 14:251-255, 1991 · DOI
  39. Meldrum B: Update on the mechanism of action of antiepileptic drugs. Epilepsia 37(suppl 6):4-11, 1996 · DOI · Paper page
  40. Betts T, Goodwin G, Withers R, et al: Human safety of lamotrigine. Epilepsia 32 (suppl 2):17-21, 1991 · DOI
  41. Hinze-Selch D, Schuld A, Kraus T, et al: Effects of antidepressants on weight and on the plasma levels of leptin, TNF-a, and soluble TNF receptors. Neuropsychopharmacology 23:13-19, 2000 · DOI
  42. Yergani V, Rohl R, Aleem A, et al: Carbohydrate craving and increased appetite associated with antidepressant therapy. Canadian Journal of Psychiatry 33:606-610, 1988 · doi:10.1177/070674378803300706
  43. Trivedi M, Rush A: A review of randomized controlled medication trials in major depression. Biological Psychiatry 31:188-189, 1992 · doi:10.1016/0006-3223(92)90650-o
  44. Fernstrom M, Krowinski R, Kupfer D: Chronic imipramine treatment and weight gain. Psychiatry Research 17:269-273, 1986 · DOI
  45. Garland E, Remick R, Zis A: Weight gain with antidepressants and lithium. Journal of Clinical Psychopharmacology 8:323-330, 1988 · DOI
  46. Paradis C, Stack J, George C, et al: Nortriptyline and weight change in depressed patients over 60. Journal of Clinical Psychopharmacology 12:246-250, 1992 · doi:10.1097/00004714-199208000-00006
  47. Gantu T, Korek J: Monoamine oxidase inhibitors and weight gain. Clinical Pharmacology 22:755-759, 1988 · DOI
  48. Delgano P, Charney D, Price L, et al: Serotonin function and the mechanism of antidepressant action. Archives of General Psychiatry 47:411-418, 1990 · DOI · Paper page
  49. Rosalinda T: Change in weight during a one-year trial with fluoxetine. Journal of Clinical Psychiatry 53:259-267, 1992
  50. Tollefson G, Holman S, Saylor M, et al: Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. Journal of Clinical Psychiatry 55:50-59, 1994
  51. Beasley C, Sayler M, Bosomworth J, et al: High dose fluoxetine: efficacy and activating-sedating effects. Journal of Clinical Psychiatry 303:685-692, 1991
  52. Bouwer C, Harvey B: Phasic craving for carbohydrate observed with citalopram. International Journal of Clinical Psychopharmacology 11:273-278, 1996 · DOI
  53. Kupfer D, Coble P, Rubinstein D: Changes in weight during treatment for depression. Psychosomatic Medicine 41:535-544, 1979 · DOI
  54. Gorman J: Mirtazapine: clinical overview. Journal of Clinical Psychiatry 60:9-12, 1999
  55. Robinson D, Roberts D, Smith J, et al: The safety profile of nefazodone. Journal of Clinical Psychiatry 57:31-37, 1996
  56. Evans S, Foltin R, Fischman M: Food "craving" and the acute effect of alprazolam on food intake in women with premenstrual dysphoric disorder. Appetite 32:331-349, 1999 · DOI

Cited by

See all 162

Metadata

Authors
Vanina, Y., Podolskaya, A., Sedky, K., Shahab, H., Siddiqui, A., Munshi, F., & Lippmann, S.
Venue
Psychiatric Services
Published
2002-07
Volume
53
Issue
7
Pages
842-847
ISSN
  • 0022-1597 (ISSN-L)
  • 1075-2730
  • 1557-9700
OpenAlex
W2159325340
Cited by
162
References
1
FWCI
5.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.